1v,w and Extended Data Fig
GLP-1RAs in the cardiovascular system In the cardiovascular system, GLP-1 can reduce cardiac ischemia-reperfusion injury through the activation of specific signaling pathways, such as the PI3K/Akt pathway
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase b (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase a (PKA) signaling pathways involving -catenin
If results slow down, your provider can help adjust the plan and keep you moving forward with a supportive, medically guided approach
Risk tolerance and verification capability affect appropriate vendor selection
Updated: 06/15/26 Download Patient SGLT2i HandoutDownload Patient GLP-1 RA Handout These one-page guide will answer your patient's most common questions when starting an SGL2i medication like Jardiance, Farxiga, Invokana, or Steglatro and GLP-1 RA medications like Ozempic, Rybelsus, Trulicity, Victoza, Bydureon BCise, or Byetta
